Pharmacological agents, including pioglitazone and SGLT2 inhibitors, have shown potential in reducing hepatic steatosis and improving metabolic parameters, yet their long-term safety and efficacy in reversing fibrosis remain uncertain [46, 47]. Here, SLC5A2 is linked to Hepatic steatosis.